GenSight Biologics (SIGHT) Stock Overview
A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
SIGHT Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
GenSight Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.08 |
| 52 Week High | €0.25 |
| 52 Week Low | €0.075 |
| Beta | 0.64 |
| 1 Month Change | -10.56% |
| 3 Month Change | -8.51% |
| 1 Year Change | -62.27% |
| 3 Year Change | -90.70% |
| 5 Year Change | -99.04% |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| SIGHT | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -4.9% | -2.6% | 1.8% |
| 1Y | -62.3% | 243.4% | 5.2% |
Return vs Industry: SIGHT underperformed the French Biotechs industry which returned 235.5% over the past year.
Return vs Market: SIGHT underperformed the French Market which returned 2.3% over the past year.
Price Volatility
| SIGHT volatility | |
|---|---|
| SIGHT Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in FR Market | 10.8% |
| 10% least volatile stocks in FR Market | 2.7% |
Stable Share Price: SIGHT has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: SIGHT's weekly volatility has decreased from 12% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 13 | Laurence Rodriguez | www.gensight-biologics.com |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration.
GenSight Biologics S.A. Fundamentals Summary
| SIGHT fundamental statistics | |
|---|---|
| Market cap | €18.66m |
| Earnings (TTM) | -€12.04m |
| Revenue (TTM) | €652.00k |
Is SIGHT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIGHT income statement (TTM) | |
|---|---|
| Revenue | €652.00k |
| Cost of Revenue | €0 |
| Gross Profit | €652.00k |
| Other Expenses | €12.69m |
| Earnings | -€12.04m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Sep 29, 2026
| Earnings per share (EPS) | -0.051 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,846.01% |
| Debt/Equity Ratio | -50.2% |
How did SIGHT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 04:02 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GenSight Biologics S.A. is covered by 7 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniil Gataulin | Chardan Capital Markets, LLC |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Guillaume Cuvillier | Gilbert Dupont |